Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciforadenant +/- Atezolizumab in Advanced Cancers
NCT02655822Phase 1Completed
- Sponsor
- Corvus Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ciforadenant in renal cell carcinoma (RCC) and metastatic castration-resistant prostate cancer (mCRPC) (5 cohorts), sponsored by Corvus Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities at 28 days, Objective Response Rate up to 72 months and 4 more. Started Jan 2016; status: completed.
02
Drugs
ciforadenant
03
Conditions
renal cell carcinoma (RCC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02655822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655822.